Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cybin Inc (NY: CYBN )

10.28 -0.04 (-0.39%)
Official Closing Price Updated: 8:00 PM EST, Dec 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Cybin Inc

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Cybin Receives Notice of Allowance from U.S. Patent Office
Cybin (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been awarded a Notice of Allowance from the U.S. Patent and Trademark Office (... 
Via Benzinga
Cybin Developing Safer, More Effective Psilocybin Therapies
Cybin (NYSE: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced positive results from a... 
Via Benzinga
Cybin to Fund, Support Psychedelic Clinic at Manhattan Hospital
Company receives grant to fund clinic for marginalized, underserved NYC communities New clini... 
Via Benzinga
Psilera's DMT-Derived Drug Sees Positive Results in Pre-Clinical Study
Psilera is a Florida-based biotechnology company focused on developing drugs to treat mental disorders using non-hallucinogenic derivatives from psychedelic compounds. The... 
Via Benzinga
Topics Derivatives
Exposures Derivatives
Cybin Touts Highlights of 'Transformative' Second-Quarter Performance
The report notes significant and swift advancements in the company R&D pipeline and overall business Preliminary data indicates CYB003 may provide significant treatment... 
Via Benzinga
Cybin Announces FDA Approvals, Participation in Conference
Cybin (NYSE: 
Via Benzinga
Exposures Product Safety
Cybin Releases Q2 Financial Results
Cybin (NYSE: 
Via Benzinga
Cybin to Release Q2 2021 Results on November 15
Cybin (NYSE: 
Via Benzinga
Cybin Inc. Receives Schedule I Manufacturing License from DEA
Cybin (NYSE: 
Via Benzinga
Psilocybin Trials For COVID-Related Distress Of Healthcare Professionals Could Validate New Psychotherapy Model
Cybin (NYSE:CYBN), a biotech company focused on progressing ... 
Via Benzinga
Cybin To Test Psychedelic-Assisted Psychotherapy For COVID-Related Distress
The FDA authorized an investigator-initiated Phase 2 trial evaluating Cybin Inc's (NYSE: CYBN) psychedelic-assisted psychotherapy with psilocybin for... 
Via Benzinga
Exposures Product Safety
Cybin Supports Psychedelic Treatment Clinic Through Grant
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first... 
Via Benzinga
NY's Lenox Hill Hospital With Cybin-Awarded Grant Will Provide Psychedelic Therapy To City's Underserved
Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: 
Via Benzinga
Psychedelic Drug Stocks Continued To Decline Last Week
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November. 
Via Talk Markets
Cybin 'One Step Closer' to Creating Best Therapy for Mental Health
Company releases positive results from a pre-clinical study focusing on psilocybin program CYB003 Multiple academic studies have shown that psilocybin may have the potential to... 
Via Benzinga
Cybin Reports Q2 Financial Results And Latest News, Including FDA & DEA Research Approvals
Toronto-based, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics,” reported its unaudited... 
Via Benzinga
Exposures Product Safety
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September. 
Via Talk Markets
Can The Psychedelics Boom Go Bust? A Conversation With Cybin Chief Clinical Officer Dr. Alex Belser
This article was originally published on Psychedelic Spotlight and appears here with permission. "Something that people used t... 
Via Benzinga
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
Compass Pathways reported 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
Cybin Unveils Data Suggesting Its Novel Psilocybin Analog Is the 'Superior Molecule'
This article was originally published on 
Via Benzinga
Cybin CEO Presenting at Jefferies London Healthcare Conference
Cybin (NYSE: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” has announced that its CEO Doug Drysdale will present at the... 
Via Benzinga
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
Shares plunged, despite a psilocybin-based drug reducing depression in a trial. 
Via Investor's Business Daily
32 Stocks Moving in Tuesday's Pre-Market Session
Gainers Dover Motorsports, Inc. (NYSE: DVD) rose 57% to $3.58 in pre-market trading. Luminar Technologies, Inc. (NASDAQ: LAZR) rose 54.2% to $26.98 in pre-market trading after... 
Via Benzinga
64 Biggest Movers From Yesterday
Gainers Pioneer Power Solutions, Inc. (NASDAQ: PPSI) shares jumped 219% to close at $10.40 on Monday after the company announced the launch of its E-Boost portfolio of mobile... 
Via Benzinga
Cybin Announces Positive Data Showing Effectiveness of Psilocybin To Treat Depression
Cybin Inc (NYSE: CYBN), a Toronto-based biotechnology company focused on utilizing psychedelic drugs as an alternative to traditional psychiatric drugs, announced positive... 
Via Benzinga
Cybin's CYB003 Demonstrates Advantages over Oral Psilocybin for Mental Health
Cybin (NYSE: 
Via Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
Detroit Decriminalizes Psychedelics 
Via Benzinga
Exposures Product Safety
Cybin Gets DEA License To Work With Scheduled Psychedelic Molecules
Cybin Inc. (NYSE:CYBN) a company developing novel psychedeli... 
Via Benzinga
Cybin Inc. Schedules R&D Briefing to Release Breakthrough Research Findings
Cybin (NEO: CYBN) (NYSE: 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.